NasdaqGS:MRNABiotechs
Moderna (MRNA) Quarterly Loss Narrows To US$200 Million Challenging Bearish Profitability Narratives
How Moderna's Latest Numbers Set the Stage for Its Next Chapter
Moderna (MRNA) has just posted third quarter FY 2025 revenue of US$1,016 million with a basic EPS loss of US$0.51 and net income loss of US$200 million, as its mRNA platform continues to move through an investment heavy phase. The company has seen quarterly revenue move from US$966 million in Q4 2024 to US$108 million in Q1 2025, US$142 million in Q2 2025 and then US$1,016 million in Q3 2025. Over the same stretch, basic EPS...